	Efalizumab
Psoriasis
Psoriatic arthritis
Arthritis
Arthropathy
	long-term treatment
arthropathy AEs
patients
efalizumab-treated patients
treatment
efalizumab treatment
long-term studies
proportion
low
placebo group
efalizumab
joint disease
arthropathy
phase
chronic plaque psoriasis
placebo
analysis
clinical response
study
data
weeks
efalizumab groups
arthropathy prior
Phase III clinical trials
baseline
similar
months
routine clinical practice
previous history
psoriasis
results
incidence
clinical trials
Fig
long-term
psoriatic arthritis
similar proportion
continuous
CI 0
trials
group
population
events
total
open-label extensions
chronic
large-scale
responses
AEs
increase
risk

